2024

12 • 20 • 2024

NervGen Announces “At-The-Market” Equity Program

11 • 14 • 2024

NervGen Pharma Reports Q3 2024 Financial Results and Operational Updates

11 • 07 • 2024

NervGen Pharma to Present at the Stifel 2024 Healthcare Conference

09 • 30 • 2024

NervGen Pharma Provides Update on Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury

09 • 20 • 2024

NervGen Pharma to Present at the Unite 2 Fight Paralysis 19th Annual Science & Advocacy Symposium Focused on Spinal Cord Injury

09 • 16 • 2024

NervGen Pharma to Present at the 63rd International Spinal Cord Society Annual Scientific Meeting

08 • 27 • 2024

NervGen Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference

08 • 22 • 2024

NervGen Pharma Reports Q2 2024 Financial Results and Operational Updates

08 • 06 • 2024

NervGen Pharma to Present at the Canaccord Genuity 44th Annual Growth Conference